5:23 PM
 | 
Apr 26, 2013
 |  BC Extra  |  Top Story

CHMP backs Xtandi, Erivedge, Nuedexta

EMA's CHMP issued a number of positive recommendations on Friday, including a recommendation to approve an MAA from Astellas Pharma Inc. (Tokyo:4503) for Xtandi enzalutamide to treat metastatic castration-resistant prostate cancer (CRPC) in men whose disease has progressed on or after docetaxel therapy. FDA approved the oral androgen receptor antagonist for...

Read the full 244 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >